Jaguar Health (NASDAQ: JAGX) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, and sustainably derived prescription medicines for people and animals with GI distress. The company's wholly owned subsidiary, Napo Pharmaceuticals (Napo), focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Napo’s Mytesi(R) (crofelemer) product is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar’s crofelemer drug product candidate is also the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Canalevia(R)-CA1 (crofelemer delayed-release tablets), the company's prescription drug product for the treatment of chemotherapy-induced diarrhea (“CID”) in dogs, received conditional approval from the FDA on December 21, 2021. Jaguar is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. For more information, visit the company’s website at https://jaguar.health.
To view IBN’s virtual coverage of Noble’s 18th annual small and micro-cap investor conference, visit https://ibn.fm/NobleCon18
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating at this year’s NobleCon. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com